AIM ImmunoTech Inc AIM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AIM is a good fit for your portfolio.
News
-
AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy
-
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
-
AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
-
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
-
AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering
-
AIM ImmunoTech to Participate in Two Upcoming Investor Conferences
-
AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update
-
AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast
Trading Information
- Previous Close Price
- $0.36
- Day Range
- $0.35–0.37
- 52-Week Range
- $0.31–0.72
- Bid/Ask
- $0.36 / $0.37
- Market Cap
- $20.85 Mil
- Volume/Avg
- 168,189 / 261,407
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 92.36
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 28
- Website
- https://www.aimimmuno.com
Valuation
|
Metric
|
AIM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.43 |
Price/Sales | 92.36 |
Price/Cash Flow | — |
Price/Earnings
AIM
Financial Strength
|
Metric
|
AIM
|
|---|---|
Quick Ratio | 1.11 |
Current Ratio | 1.14 |
Interest Coverage | — |
Quick Ratio
AIM
Profitability
|
Metric
|
AIM
|
|---|---|
Return on Assets (Normalized) | −114.58% |
Return on Equity (Normalized) | −155.15% |
Return on Invested Capital (Normalized) | −145.13% |
Return on Assets
AIM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Gymhzlfssj | Tqj | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Xngwgxbt | Zprjd | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Tmcxgky | Dpvls | $118.7 Bil | |||
| Moderna Inc
MRNA
| Dhybykgl | Zsh | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Wgrwrcsgr | Gyzxfx | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Jrknsqcr | Dls | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Htsyqcrf | Vmv | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Qzdrntzxk | Ltghrj | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Qzcbqyk | Cmcf | $15.0 Bil | |||
| Incyte Corp
INCY
| Pftkyqb | Sxzcdk | $13.5 Bil |